Prevalence of drug-resistant HIV reaches ‘alarming levels’ in Aruba

The prevalence of resistance to nonnucleoside reverse transcriptase inhibitors among HIV-infected individuals has increased to ‘alarming levels’ in Aruba, reaching 45% in 2015, researchers reported.

L. Marije Hofstra, MD, of the department of medical microbiology at the University Medical Center Utrecht, the Netherlands, and colleagues discovered that the increase in resistance is due to a rise in the nonnucleoside reverse transcriptase inhibitor (NNRTI)-mutation K103N. The mutation has a detrimental effect against Sustiva (efavirenz, Bristol-Myers Squibb) and nevirapine, which are commonly used in first-line combination ART (cART) regimens in high-endemic countries.

“Emergence of HIV drug resistance during cART use has tremendously decreased in Western countries, and transmission of drug resistance has merely stabilized in recent years, as a result of close laboratory monitoring, the use of regimens with a higher genetic barrier to resistance, and surveillance,” Hofstra, who also is fromthe department of infection and immunity at Luxembourg Institute of Health, and colleagues wrote in Clinical Infectious Diseases. “However, our data demonstrate that in a setting without adequate surveillance, the prevalence of infections with NNRTI-resistant HIV can increase to worrisome levels, compromising the efficacy of the standard first-line NNRTI-based regimen.”

The researchers examined data on 104 treatment-naive participants who underwent HIV drug-resistance testing from 2010 to 2015 in Aruba. Among them, 86% were men, 39% were foreign-born and 22% had AIDS at diagnosis.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below